Eoneren/E+ via Getty Images Short interest for healthcare stocks in S&P 500 increased during September end vs.

Moderna Therapeutics (NASDAQ: MRNA) was once the darling of the healthcare space for investors. The company emerged as one of the biggest names of the COVID-19 pandemic with its vaccine.

Moderna had a good run up the price charts to start 2024, but the healthcare stock is now down 33% for the year to date. Still, Wall Street remains bullish on the drugmaker. According to S&P ...

Moderna's shares have dropped over 41.67% since I last wrote on them due to high costs, particularly in R&D, and increased competition, making their financial outlook murky. Cost-cutting measures ...

The PCMPA has slammed Moderna over an unapproved WhatsApp message that offered children in the U.K. 1,500 pounds sterling ($2,000) to participate in a clinical trial of its COVID-19 booster vaccine.

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even. The company also ...

In today's trading context, the average open interest for options of Moderna stands at 1500.79, with a total volume reaching 847.00. The accompanying chart delineates the progression of both call ...

Moderna's updated COVID-19 vaccine was approved by Health Canada. The updated vaccine targets the KP.2 variant. Moderna, Inc. MRNA shares are moving higher on Tuesday after the company announced ...

On Tuesday, Health Canada announced it had approved Moderna’s latest COVID vaccine that’s been reformulated to target prevalent variants like KP.2. The updated formula will be available to ...

Moderna was a huge pandemic name, but has struggled since the earlier days of the health crisis. The company is looking to introduce new products and then lower its R&D budget. Even after its sell ...